Related Experiment Video

Updated: Feb 28, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.0K

miR-200b inhibits CD133+ glioma cells by targeting the AKT pathway

Aiqun Liu1,2, Qingyun Yu2, Zhongxing Peng2

  • 1Department of Neurology, Jinan University, Guangzhou, Guangdong, 510632, P.R. China.

Oncology Letters
|June 11, 2017
PubMed

Insights

MicroRNA-200b (miR-200b) acts as a tumor suppressor by inhibiting CD133+ glioma cells. This study reveals miR-200b targets PROM1, suppressing glioma stem cell properties and proliferation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Neuroscience

Background:

  • MicroRNA-200b (miR-200b) is a known tumor suppressor.
  • CD133 is a marker for normal and cancer stem cells, but its role in glioma is unclear.
  • Glioma is a primary brain tumor with significant unmet medical needs.

Purpose of the Study:

  • To investigate the function and mechanism of miR-200b in suppressing CD133-positive (CD133+) glioma cells.
  • To elucidate the role of the miR-200b/CD133 axis in glioma stem cell behavior.

Main Methods:

  • Isolation of CD133+ glioma cells via flow cytometry.
  • Quantitative PCR and Western blot analysis to assess gene and protein expression (miR-200b, CD133, PROM1, AKT, Notch1).
  • Luciferase reporter assay to confirm miR-200b binding to PROM1; Bromodeoxyuridine staining for cell proliferation analysis.

Main Results:

  • Glioma samples showed an inverse correlation between CD133 expression and miR-200b levels.
  • Prominin 1 (PROM1), the gene encoding CD133, was validated as a direct target of miR-200b.
  • miR-200b significantly inhibited stemness and proliferation in CD133+ glioma cells.
  • A miR-200b/CD133/PI3K/Akt signaling pathway was identified.

Conclusions:

  • miR-200b functions as a tumor suppressor in glioma by targeting CD133.
  • The miR-200b/CD133 interaction regulates glioma stem cell characteristics.
  • This study uncovers a critical signaling axis involved in glioma progression and offers potential therapeutic targets.
Keywords:
AktCD133gliomamiR-200b

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K